Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks how well a targeted lung cancer drug works in everyday clinics

NCT ID NCT05703516

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 44 people in South Korea who have a specific type of lung cancer (NSCLC with MET exon 14 skipping mutation) and are taking the drug Capmatinib (Tabrecta). Researchers will monitor side effects and how well the drug shrinks tumors in real-world settings, not in a controlled lab environment. The goal is to confirm the drug's safety and effectiveness as it is used by doctors in routine practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Capmatinib (Tabrecta)
What this could lead to
If successful, this study will confirm that Capmatinib is safe and effective for treating a specific type of lung cancer in everyday clinical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects are possible, and the small size (44 people) limits general conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who receive Tabrecta® (Capmatinib) as per locally approved label.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study. * Subject who are diagnosed as exon 14 skipping mutated NSCLC from tissue or plasma(ctDNA) sample analysis by treating physician (i.e. Any kind of diagnostic methods the institution currently has. Diagnostic modalities for research purpose would be also allowable.) * Subject who plan to receive Tabrecta® (Capmatinib) as per locally approved label Exclusion Criteria: * Subject with contraindication according to the locally approved label * Subject whose medical record is not accessible * Subject who are not willing to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Daegu, Dalseo gu, 42602, South Korea

  • Novartis Investigative Site

    RECRUITING

    Suwon, Gyeonggi-do, 16499, South Korea

  • Novartis Investigative Site

    RECRUITING

    Incheon, Korea, 405 760, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Korea, 02447, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 602-030, South Korea

  • Novartis Investigative Site

    RECRUITING

    Daejeon, 302-241, South Korea

  • Novartis Investigative Site

    RECRUITING

    Jeollanam, 519763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.